{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:57:18Z","timestamp":1763017038073},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,28]],"date-time":"2010-06-28T00:00:00Z","timestamp":1277683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,6,28]],"date-time":"2010-06-28T00:00:00Z","timestamp":1277683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1038\/bmt.2010.160","type":"journal-article","created":{"date-parts":[[2010,6,28]],"date-time":"2010-06-28T10:52:35Z","timestamp":1277722355000},"page":"510-515","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma"],"prefix":"10.1038","volume":"46","author":[{"given":"S M A","family":"Kazmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R M","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Anderlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R E","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S A","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M H","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,28]]},"reference":[{"key":"BFbmt2010160_CR1","unstructured":"Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N et al. SEER cancer statistics review, 1975\u20132006. National Cancer Institute: Bethesda, 2008. Available from http:\/\/seer.cancer.gov\/csr\/1975_2006\/ based on November 2008 SEER data submission, posted to the SEER website, 2009."},{"key":"BFbmt2010160_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto KL, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt2010160_CR3","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt2010160_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929\u2013936.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010160_CR5","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","volume":"106","author":"J Blade","year":"2005","unstructured":"Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755\u20133759.","journal-title":"Blood"},{"key":"BFbmt2010160_CR6","first-page":"7","volume":"136","author":"LG Conte","year":"2008","unstructured":"Conte LG, Figueroa MG, Lois VV, Cabrera CME, Leon RA, Garcia LH et al. Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system. Rev Med Chil 2008; 136: 7\u201312.","journal-title":"Rev Med Chil"},{"key":"BFbmt2010160_CR7","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.bbmt.2007.05.014","volume":"13","author":"MH Qazilbash","year":"2007","unstructured":"Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007; 13: 1066\u20131072.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010160_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1080\/10428190500520806","volume":"47","author":"MH Qazilbash","year":"2006","unstructured":"Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A et al. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 2006; 47: 1360\u20131364.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2010160_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/sj.bmt.1703035","volume":"27","author":"R Alexanian","year":"2001","unstructured":"Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037\u20131043.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010160_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/bmt.2009.176","volume":"45","author":"M Wang","year":"2010","unstructured":"Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 2010; 45: 498\u2013504.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010160_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200\u2009mg\/m(2) melphalan and 8\u2009Gy total body irradiation plus 140\u2009mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731\u2013735.","journal-title":"Blood"},{"key":"BFbmt2010160_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2141.2005.05641.x","volume":"130","author":"R Fenk","year":"2005","unstructured":"Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 2005; 130: 588\u2013594.","journal-title":"Br J Haematol"},{"key":"BFbmt2010160_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/sj.bmt.1703007","volume":"27","author":"A Shimoni","year":"2001","unstructured":"Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001; 27: 821\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010160_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1046\/j.1365-2141.2003.04067.x","volume":"120","author":"JJ Lahuerta","year":"2003","unstructured":"Lahuerta JJ, Grande C, Martinez-Lopez J, De La Serna J, Toscano R, Ortiz MC et al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos\/Trasplante Autologo de Medula Osea phase II trial. Br J Haematol 2003; 120: 296\u2013303.","journal-title":"Br J Haematol"},{"key":"BFbmt2010160_CR15","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","volume":"27","author":"A Spencer","year":"2009","unstructured":"Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27: 1788\u20131793.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010160_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.1998.16.2.589","volume":"16","author":"EH Kraut","year":"1998","unstructured":"Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA et al. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 589\u2013592.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010160_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.leukres.2005.03.003","volume":"29","author":"EH Kraut","year":"2005","unstructured":"Kraut EH, Young D, Farag S, James AG, Solove RJ . Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma. Leuk Res 2005; 29: 1233\u20131234.","journal-title":"Leuk Res"},{"key":"BFbmt2010160_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","volume":"27","author":"O Fitoussi","year":"2001","unstructured":"Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837\u2013842.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010160_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbmt2010160_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842\u2013854.","journal-title":"Cancer"},{"key":"BFbmt2010160_CR21","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/cncr.20294","volume":"100","author":"A Anagnostopoulos","year":"2004","unstructured":"Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004; 100: 2607\u20132612.","journal-title":"Cancer"},{"key":"BFbmt2010160_CR22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.leukres.2006.09.021","volume":"31","author":"DM Benson Jr","year":"2007","unstructured":"Benson Jr DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res 2007; 31: 1069\u20131075.","journal-title":"Leuk Res"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2010160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010160","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:21:02Z","timestamp":1648041662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2010160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,28]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["BFbmt2010160"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2010.160","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,28]]},"assertion":[{"value":"11 January 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}